Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR)
<p><strong>Objective:</strong> To examine the effects of filgotinib, an oral, selective Janus kinase 1 inhibitor, on health-related quality of life (HRQoL) using the Psoriatic Arthritis Impact of Disease (PsAID)9 questionnaire in active PsA.</p> <p><strong>Methods...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Published: |
Oxford University Press
2019
|